

IVI partners with Hilleman to advance vaccine R&D and manufacturing

04 October 2022 | News

Signs MoU of 3 years to establish a joint R&D pursuit to expand access to safe, effective, and affordable Vaccinesin Low-and Middle-Income countries



South Korea-based International Vaccine Institute (IVI) has signed a three-year Memorandum of Understanding (MoU) with Hilleman Laboratories to establish a pursuit of joint R&D for vaccine development to broaden the availability of safe, effective, and affordable vaccines in low- and middle-income countries (LMICs).

Under the MoU, IVI and Hilleman Laboratories will develop joint funding frameworks for R&D and manufacturing of affordable vaccines to LMICs. The collaboration is intended to include activities such as early development of novel or improved vaccines, candidate selection, design, manufacturing process development, and clinical studies.

Partnership will leverage Hilleman's expertise at vaccine development and manufacturing, and taps into IVI's experienced clinical and EPI teams, which will advance vaccine candidates from clinical development through to commercialization.

"We are looking forward to accelerate broad and equitable access to vaccines with IVI for populations in LMICs, specifically in areas with high unmet public health needs," said Dr Raman Rao, Chief Executive Officer, Hilleman Laboratories.